MA34650B1 - Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane - Google Patents

Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane

Info

Publication number
MA34650B1
MA34650B1 MA35880A MA35880A MA34650B1 MA 34650 B1 MA34650 B1 MA 34650B1 MA 35880 A MA35880 A MA 35880A MA 35880 A MA35880 A MA 35880A MA 34650 B1 MA34650 B1 MA 34650B1
Authority
MA
Morocco
Prior art keywords
cgrp
agonists
piperidinone carboxamide
carboxamide azaindane
receptor
Prior art date
Application number
MA35880A
Other languages
English (en)
Inventor
Ian M Bell
Mark E Fraley
Steven N Gallicchio
Anthony Ginnetti
Helen J Mitchell
Daniel V Paone
Donnette D Staas
Cheng Wang
C Blair Zartman
Heather E Stevenson
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MA34650B1 publication Critical patent/MA34650B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des dérivés de pipéridinone carboxamide azaindane de formule I qui sont des antagonistes des récepteurs CGRP et sont utiles dans le traitement ou la prévention de maladies dans lesquelles le CGRP est impliqué, comme la migraine. L'invention concerne aussi les compositions pharmaceutiques comprenant ces composés et l'utilisation de ces composés et compositions dans la prévention ou le traitement de ces maladies dans lesquelles le CGRP est impliqué.
MA35880A 2010-11-12 2013-05-06 Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane MA34650B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41307710P 2010-11-12 2010-11-12
US201061425034P 2010-12-20 2010-12-20
PCT/US2011/060081 WO2012064910A1 (fr) 2010-11-12 2011-11-10 Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane

Publications (1)

Publication Number Publication Date
MA34650B1 true MA34650B1 (fr) 2013-11-02

Family

ID=45034191

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35880A MA34650B1 (fr) 2010-11-12 2013-05-06 Antagonistes du récepteur cgrp de pipéridinone carboxamide azaindane

Country Status (43)

Country Link
US (8) US8481556B2 (fr)
EP (2) EP2821407B1 (fr)
JP (1) JP5642883B2 (fr)
KR (1) KR101537877B1 (fr)
CN (1) CN103328478B (fr)
AR (1) AR083831A1 (fr)
AU (1) AU2011326454B2 (fr)
BR (1) BR112013011448B8 (fr)
CA (1) CA2817100C (fr)
CL (1) CL2013001289A1 (fr)
CO (1) CO6801723A2 (fr)
CR (1) CR20130214A (fr)
CY (2) CY1118362T1 (fr)
DK (2) DK2638042T3 (fr)
DO (1) DOP2013000103A (fr)
EA (1) EA022850B1 (fr)
EC (1) ECSP13012676A (fr)
ES (2) ES2604827T3 (fr)
FI (1) FIC20230034I1 (fr)
FR (1) FR23C1039I2 (fr)
GT (1) GT201300122A (fr)
HR (2) HRP20141108T1 (fr)
HU (2) HUE031010T2 (fr)
IL (1) IL225978A (fr)
LT (2) LT2821407T (fr)
LU (1) LUC00321I2 (fr)
MA (1) MA34650B1 (fr)
ME (2) ME02552B (fr)
MX (1) MX2013005246A (fr)
MY (1) MY165113A (fr)
NI (1) NI201300043A (fr)
NL (1) NL301248I2 (fr)
NO (1) NO2023040I1 (fr)
NZ (1) NZ610468A (fr)
PE (1) PE20140240A1 (fr)
PH (1) PH12013500958A1 (fr)
PL (2) PL2638042T3 (fr)
PT (2) PT2821407T (fr)
RS (2) RS53610B1 (fr)
SG (2) SG190137A1 (fr)
SI (2) SI2821407T1 (fr)
TW (3) TWI501968B (fr)
WO (1) WO2012064910A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI501968B (zh) * 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012129013A1 (fr) 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
WO2013138418A2 (fr) * 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Procédé de production d'antagonistes du récepteur cgrp
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2015038736A2 (fr) * 2013-09-16 2015-03-19 Merck Sharp & Dohme Corp. Formulations pour antagonistes du récepteur cgrp
US10117836B2 (en) * 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
FR3030521B1 (fr) * 2014-12-23 2019-07-26 Galderma Research & Development Nouveaux composes heterocycliques et leur utilisation en medecine ainsi qu'en cosmetique
GB201707938D0 (en) 2017-05-17 2017-06-28 Univ Sheffield Compounds
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
US20190374520A1 (en) * 2018-06-08 2019-12-12 Allergan Pharmaceuticals International Limited Treatment of migraine
GB201908430D0 (en) * 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
GB201908420D0 (en) 2019-06-12 2019-07-24 Heptares Therapeutics Ltd Cgrp antagonist compounds
CN110787163B (zh) * 2019-12-05 2020-06-02 河北医科大学第二医院 一种用于神经保护和促进神经再生的药物组合物及其制剂
MX2023001071A (es) 2020-07-29 2023-05-12 Allergan Pharmaceuticals Int Ltd Tratamiento de la migraña.
CN116096361B (zh) * 2020-08-07 2025-10-10 大鹏药品工业株式会社 新型环烯酮化合物或其盐
CN112353767A (zh) * 2020-11-16 2021-02-12 海南锦瑞制药有限公司 一种盐酸地尔硫卓和普瑞巴林组合物及其制备方法及其应用
CN116456981A (zh) * 2020-11-19 2023-07-18 辉瑞爱尔兰制药公司 用于改善的grp抑制剂递送的组合物
CA3206184A1 (fr) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Traitement de la migraine
JP2024509165A (ja) 2021-03-02 2024-02-29 シージーアールピー ダイアグノスティクス ゲーエムベーハー 片頭痛の治療及び／又は発生の低減
WO2023026205A1 (fr) 2021-08-24 2023-03-02 Cgrp Diagnostics Gmbh Traitement préventif de la migraine
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
WO2023119327A1 (fr) * 2021-12-20 2023-06-29 Msn Laboratories Private Limited, R&D Center Procédé de préparation d'une forme amorphe pure d'ubrogepant
US20250353860A1 (en) * 2022-04-29 2025-11-20 Brise Pharmaceuticals Co., Ltd. Piperidine carboxamide azaindane derivative, method for preparing same, and use thereof
US20260130901A1 (en) 2022-10-11 2026-05-14 Allergan Pharmaceuticals International Limited Cgrp receptor antagonist for the treatment of migraine
WO2024134683A1 (fr) * 2022-12-21 2024-06-27 Msn Laboratories Private Limited, R&D Center Nouvelle méthode de préparation de composés intermédiaires utilisés dans le traitement de la migraine
WO2024218790A1 (fr) * 2023-04-15 2024-10-24 Msn Laboratories Private Limited, R&D Center Composition pharmaceutique d'ubrogépant et procédé correspondant pour la préparation d'une forme posologique solide destinée au traitement de la migraine
CN118834160B (zh) * 2023-04-23 2025-12-19 中国医学科学院药物研究所 Ubrelvy关键手性内酰胺中间体及其衍生物的不对称合成方法
CN119431222B (zh) * 2024-11-04 2025-10-17 杭州澳赛诺生物科技有限公司 一种不对称合成乌布吉泮手性中间体的方法
CN119350337A (zh) * 2024-12-24 2025-01-24 药康众拓(北京)医药科技有限公司 一类氘代哌啶酮酸酰胺氮杂茚满类cgrp抑制剂药物及用途

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
EP1606286B1 (fr) 2003-03-14 2011-05-11 Merck Sharp & Dohme Corp. Antagonistes benodiazepine spirohydantoin des recepteurs de cgrp
US7288559B2 (en) 2003-03-14 2007-10-30 Merck + Co, Inc. Carboxamide spirohydantoin CGRP receptor antagonists
JO2355B1 (en) * 2003-04-15 2006-12-12 ميرك شارب اند دوم كوربوريشن Hereditary calcitonin polypeptide receptor antagonists
US7390798B2 (en) 2004-09-13 2008-06-24 Merck & Co., Inc. Carboxamide spirolactam CGRP receptor antagonists
US8003792B2 (en) * 2004-09-13 2011-08-23 Merck Sharp & Dohme Corp. Bicyclic anilide spirolactam CGRP receptor antagonists
EP1861399B1 (fr) * 2005-03-14 2011-12-14 Merck Sharp & Dohme Corp. Antagonistes du recepteur du cgrp
WO2007133491A1 (fr) * 2006-05-09 2007-11-22 Merck & Co., Inc. Antagonistes de récepteurs cgrp monocycliques substitués
CA2689217C (fr) * 2007-06-05 2016-02-16 Merck & Co., Inc. Antagonistes des recepteurs cgrp a base de carboxamide heterocyclique
EP2225237A2 (fr) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Composés organiques
US8044043B2 (en) * 2008-04-11 2011-10-25 Bristol-Myers Squibb Company CGRP receptor antagonists
US8765763B2 (en) * 2009-06-05 2014-07-01 Boehringer Ingelheim International Gmbh Substituted piperazines as CGRP antagonists
WO2012064911A1 (fr) * 2010-11-12 2012-05-18 Merck Sharp & Dohme Corp. Pipéridinone carboxamide indanes, antagonistes du récepteur cgrp
TWI501968B (zh) * 2010-11-12 2015-10-01 Merck Sharp & Dohme 六氫吡啶酮甲醯胺氮雜茚滿ｃｇｒｐ受體拮抗劑
WO2012087777A1 (fr) * 2010-12-22 2012-06-28 Merck Sharp & Dohme Corp. Antagonistes des récepteurs du cgrp indanecarboxamides hétérocycliques condensés
EP2654423B1 (fr) * 2010-12-22 2016-12-07 Merck Sharp & Dohme Corp. Antagonistes azaindane carboxamides hétérocycliques fusionnés de récepteurs du cgrp
WO2012129013A1 (fr) * 2011-03-18 2012-09-27 Merck Sharp & Dohme Corp. Pipéridinone carboxamide spirohydantoïne, antagonistes du récepteur cgrp
EP2753640B1 (fr) * 2011-09-08 2016-03-09 Codexis, Inc. Biocatalyseurs et procédés pour synthèse de lactames substitués
WO2013138418A2 (fr) * 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Procédé de production d'antagonistes du récepteur cgrp
WO2013138413A1 (fr) * 2012-03-14 2013-09-19 Merck Sharp & Dohme Corp. Sels alcaloïdes bis-quaternaires de quinquina à titre de catalyseurs par transfert de phase asymétrique
US9227972B2 (en) * 2012-05-09 2016-01-05 Merck Sharp & Dohme Corp. Aliphatic spirolactam CGRP receptor antagonists
US9174989B2 (en) * 2012-05-09 2015-11-03 Merck Sharp & Dohme Corp. Process for making CGRP receptor antagonists
WO2013169563A1 (fr) * 2012-05-09 2013-11-14 Merck Sharp & Dohme Corp. Antagonistes de récepteur de cgrp à base de pyridine
EP2846799B1 (fr) * 2012-05-09 2017-11-15 Merck Sharp & Dohme Corp. Antagonistes de récepteur de cgrp à base de spirolactame
WO2015038736A2 (fr) * 2013-09-16 2015-03-19 Merck Sharp & Dohme Corp. Formulations pour antagonistes du récepteur cgrp
US10117836B2 (en) * 2014-02-05 2018-11-06 Merck Sharp & Dohme Corp. Tablet formulation for CGRP active compounds
CN106456662A (zh) * 2014-02-24 2017-02-22 奥利金制药公司 口服给药的戊聚糖多硫酸盐的组合物及其使用方法
US20180092899A1 (en) * 2016-09-30 2018-04-05 Merck Sharp & Dohme Corp. Method of treating acute migraine with cgrp-active compound

Also Published As

Publication number Publication date
PH12013500958A1 (en) 2013-07-15
AU2011326454A1 (en) 2013-05-23
EP2638042B1 (fr) 2014-09-24
DOP2013000103A (es) 2013-10-15
SG10201509335VA (en) 2015-12-30
RS53610B1 (sr) 2015-04-30
KR101537877B1 (ko) 2015-07-17
CN103328478B (zh) 2015-10-07
US10272077B2 (en) 2019-04-30
IL225978A0 (en) 2013-06-27
ME01922B (me) 2015-05-20
EP2638042A1 (fr) 2013-09-18
MX2013005246A (es) 2013-05-28
HRP20141108T1 (hr) 2015-01-16
EP2821407B1 (fr) 2016-09-21
JP2013542260A (ja) 2013-11-21
BR112013011448B1 (pt) 2021-06-01
HK1200163A1 (en) 2015-07-31
DK2821407T3 (da) 2017-01-02
KR20130087037A (ko) 2013-08-05
SI2638042T1 (sl) 2015-01-30
US9833448B2 (en) 2017-12-05
TWI522355B (zh) 2016-02-21
US20120122911A1 (en) 2012-05-17
TWI487706B (zh) 2015-06-11
NZ610468A (en) 2015-06-26
LUC00321I2 (fr) 2026-02-02
EP2821407A1 (fr) 2015-01-07
TWI501968B (zh) 2015-10-01
ECSP13012676A (es) 2013-08-30
US20190275024A1 (en) 2019-09-12
CA2817100A1 (fr) 2012-05-18
FIC20230034I1 (fi) 2023-11-10
US20150005330A1 (en) 2015-01-01
RS55416B1 (sr) 2017-04-28
US9499545B2 (en) 2016-11-22
ME02552B (fr) 2017-02-20
SI2821407T1 (sl) 2016-12-30
TW201520214A (zh) 2015-06-01
AU2011326454B2 (en) 2015-05-21
US8754096B2 (en) 2014-06-17
PL2638042T3 (pl) 2015-03-31
EA201390683A1 (ru) 2013-09-30
HUS2300037I1 (hu) 2023-11-28
SG190137A1 (en) 2013-07-31
IL225978A (en) 2015-11-30
HRP20161641T1 (hr) 2017-01-13
NI201300043A (es) 2013-07-01
NO2023040I1 (no) 2023-10-20
FR23C1039I1 (fr) 2023-12-08
US20120122899A1 (en) 2012-05-17
AR083831A1 (es) 2013-03-27
NL301248I2 (nl) 2023-11-20
TW201520213A (zh) 2015-06-01
PT2821407T (pt) 2016-12-06
MY165113A (en) 2018-02-28
US20210008055A1 (en) 2021-01-14
GT201300122A (es) 2015-06-02
WO2012064910A1 (fr) 2012-05-18
FR23C1039I2 (fr) 2024-11-15
HUE031010T2 (en) 2017-06-28
PE20140240A1 (es) 2014-03-14
LTPA2023532I1 (fr) 2023-11-27
ES2604827T3 (es) 2017-03-09
PT2638042E (pt) 2014-12-09
TW201305165A (zh) 2013-02-01
CN103328478A (zh) 2013-09-25
CO6801723A2 (es) 2013-11-29
US20120122900A1 (en) 2012-05-17
LTC2638042I2 (fr) 2025-07-10
US8481556B2 (en) 2013-07-09
PL2821407T3 (pl) 2017-04-28
CR20130214A (es) 2013-06-28
CA2817100C (fr) 2015-09-29
CL2013001289A1 (es) 2013-08-09
LT2821407T (lt) 2016-12-12
BR112013011448A2 (pt) 2016-08-09
CY2023022I1 (el) 2024-02-16
US8912210B2 (en) 2014-12-16
DK2638042T3 (en) 2015-01-05
JP5642883B2 (ja) 2014-12-17
CY1118362T1 (el) 2017-06-28
ES2525021T3 (es) 2014-12-16
BR112013011448B8 (pt) 2022-03-29
US20180092900A1 (en) 2018-04-05
EA022850B1 (ru) 2016-03-31
US20170027925A1 (en) 2017-02-02

Similar Documents

Publication Publication Date Title
JO2355B1 (en) Hereditary calcitonin polypeptide receptor antagonists
ATE394400T1 (de) Bicyclische anilidspirohydantoine als cgrp- rezeptorantagonisten
EA201390683A1 (ru) Пиперидинонкарбоксамидазаинданы - антагонисты рецептора cgrp
ATE464304T1 (de) Carboxamid-spirolactam-cgrp-rezeptor-antagonist n
NO20092470L (no) Substituerte diazepanforbindelser som orexinreseptorantagonister
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA31117B1 (fr) Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoïdes
MA33178B1 (fr) Pipéridines substituées comme antagonistes de ccr3
MA35576B1 (fr) Nouveaux composés
MA47043A1 (fr) Composés indole carboxamides utiles comme inhibiteurs de kinase
MA33155B1 (fr) Composes organiques et leurs utilisations
TN2009000524A1 (en) Novel dicarboxylic acid derivatives as s1p1 receptor agonists
ATE535514T1 (de) Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
MA32466B1 (fr) Derives de triazole utiles pour le traitement de maladies
EA200602062A1 (ru) Амидосоединения и их применение в качестве фармацевтических средств
EP1605936A4 (fr) Antagonistes du recepteur cgrp d'aryl spirohydantoine
ATE464305T1 (de) Bicyclische anilidspirolactame als antagonisten des cgrp-rezeptors
ATE466860T1 (de) Cgrp-rezeptorantagonisten
WO2005000807A3 (fr) Antagonistes du recepteur cgrp de benzodiazepine
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA30077B1 (fr) 3-aminocyclopentanecarboxamides servant de modulateurs de recepteurs de chimiokines
TW200608960A (en) 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
MA32282B1 (fr) Dérivés de 2-phényl-pyridine substitués
ATE537170T1 (de) Cgrp-rezeptorantagonisten
EP1794146A4 (fr) Antagoniste des recepteurs cgrp spirohydantoin anilide tricyclique